There’s a concept in cell therapy that sounds like it belongs in a computer science lecture, not an oncology clinic: logic gates. IF the cell sees target A on the tumor surface, AND it does NOT see marker B on healthy cells, THEN attack. That’s Boolean logic — running inside a living immune cell. And Senti Biosciences just published the peer-reviewed science behind it in Cell Systems.
The paper details Senti’s Gene Circuit platform — specifically how they engineer NOT-gated CARs using an activating receptor (aCAR) that targets CD33 or FLT3 on leukemia cells, paired with an inhibitory receptor (iCAR) built on LIR1-based signaling through SHP-1 phosphatase. The inhibitory gate recognizes EMCN on healthy bone marrow cells and tells the CAR-NK cell to stand down. Attack the cancer. Spare the marrow.
This matters because AML is one of the most heterogeneous cancers out there. Single-target CAR therapies struggle because leukemia cells express different surface markers from patient to patient — and sometimes within the same patient. Senti’s dual-targeting approach (CD33 OR FLT3) casts a wider net, while the NOT gate prevents the collateral damage that has plagued earlier attempts.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
And here’s where the clinical data — limited as it is — starts to get interesting. SENTI-202, the off-the-shelf CAR-NK therapy built on this platform, completed Phase 1 enrollment in February 2026 for relapsed/refractory AML. Earlier data showed that two of the first three patients treated at the lowest dose achieved complete remission confirmed by bone marrow biopsy, with both assessed as MRD-negative. At the lowest dose. With an off-the-shelf product. The therapy has FDA Orphan Drug Designation.
Senti isn’t just a one-trick shop, either. Their Gene Circuit platform has attracted serious partners — Spark Therapeutics (Roche) licensed the technology in a deal worth over $645 million in biobucks for CNS and liver gene therapies, and BlueRock Therapeutics (Bayer) is using it for iPSC-based regenerative medicine. The pipeline includes SENTI-301A for hepatocellular carcinoma (partnered with Celest Therapeutics) and SENTI-401 for colorectal cancer.
Peer-reviewed validation of the underlying platform science, combined with early clinical signals in a brutal indication — that’s the kind of one-two punch that gets noticed. The question now is whether the higher dose cohort confirms what the low dose suggested. If it does, Senti’s logic gates might just rewrite how we think about tumor selectivity.
